Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kuros completes enrolment in phase IIb trial of bone regeneration product

This article was originally published in Clinica

Executive Summary

Kuros Biosurgery (Zurich, Switzerland) has enrolled the final patient in a phase IIb trial of its lead bone regeneration product, KUR-111, in tibial plateau fractures. The product is a mouldable putty that is applied directly to the fracture site. The 183-patient trial will evaluate whether the material can provide physical support and promote bone healing via the release of parathyroid hormone as successfully as autografting, the current standard of care. The primary endpoint is the rate of radiological fracture healing 16 weeks after surgery. The trial will also assess the safety of KUR-111, with results expected in early 2010.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042903

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel